Relmada Therapeutics (RLMD) Return on Capital Employed Growth (1y) (2015 - 2026)
Relmada Therapeutics (RLMD) Return on Capital Employed Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 69,146.49 Bn | 69,146.20 Bn | - | 1,648.00 |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | 31,429.00 |
| 4 | BeOne Medicines | 475.42 Bn | 470.63 Bn | 1.35 Bn | 1,805.00 |
| 5 | Vertex Pharmaceuticals | 123.32 Bn | 116.08 Bn | 2.59 Bn | 2,503.00 |
| 6 | Regeneron Pharmaceuticals | 69.80 Bn | 61.04 Bn | 3.31 Bn | -105.00 |
| 7 | Belite Bio | 63.28 Bn | 63.28 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.48 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.15 Bn | 38.15 Bn | - | -3,457.00 |
| 10 | Relmada Therapeutics | 462.43 Mn | 462.43 Mn | - | 21,129.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21,129.00 |
| Dec 31, 2025 | 8,414.00 |
| Sep 30, 2025 | -28,591.00 |
| Jun 30, 2025 | -23,216.00 |
| Mar 31, 2025 | -12,571.00 |
| Dec 31, 2024 | -9,348.00 |
| Sep 30, 2024 | -5,791.00 |
| Jun 30, 2024 | -2,250.00 |
| Mar 31, 2024 | -1,269.00 |
| Dec 31, 2023 | -1,141.00 |
| Sep 30, 2023 | -2,109.00 |
| Jun 30, 2023 | -3,187.00 |
| Mar 31, 2023 | -4,495.00 |
| Dec 31, 2022 | -1,387.00 |
| Sep 30, 2022 | 4,937.00 |
| Jun 30, 2022 | 1,354.00 |
| Mar 31, 2022 | 683.00 |
| Dec 31, 2021 | -3,281.00 |
| Sep 30, 2021 | -9,809.00 |
| Jun 30, 2021 | -5,925.00 |